Advice
In the absence of a submission from the holder of the marketing authorisation
choriogonadotropin (Ovitrelle) is not recommended for use within NHS Scotland for the treatment of anovulatory or oligo-ovulatory women.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- choriogonadotropin alfa (Ovitrelle)
- SMC ID:
- 264/06
- Indication:
- Anovulatory or oligo-ovulatory women
- Pharmaceutical company
- Serono Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 May 2006